Recent developments of RNA-based vaccines in cancer immunotherapy

References

• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011 Dec 21;480(7378):480–489.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Butterfield LH. Cancer vaccines. Bmj. 2015 Apr;22(350):h988.
   Web of Science ®Google Scholar
• Guo C, Manjili MH, Subjeck JR, et al. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. 2013;119:421–475.
   PubMed Web of Science ®Google Scholar
• Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet. 2008 Oct;9(10):776–788.
   PubMed Web of Science ®Google Scholar
• Lundstrom K. Replicon RNA viral vectors as vaccines. Vaccines (Basel). 2016 Nov 7;4(4):39.
   Google Scholar
• Vogel AB, Lambert L, Kinnear E, et al. Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses. Mol Ther. 2018 Feb 7;26(2):446–455.
   PubMed Web of Science ®Google Scholar
• Fuller DH, Berglund P. Amplifying RNA vaccine development. N Engl J Med. 2020;382(25):2469–2471.
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Mason PW, Geall A, et al. RNA-based vaccines. Vaccine. 2012 Jun 22;30(30):4414–4418.
   PubMed Web of Science ®Google Scholar
• Kavanagh DG, Kaufmann DE, Sunderji S, et al. Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef. Blood. 2006 Mar 1;107(5):1963–1969.
   PubMed Web of Science ®Google Scholar
• Melhem NM, Liu XD, Boczkowski D, et al. Robust CD4+ and CD8+ T cell responses to SIV using mRNA-transfected DC expressing autologous viral Ag. Eur J Immunol. 2007 Aug;37(8):2164–2173.
   PubMed Web of Science ®Google Scholar
• Van Nuffel AM, Benteyn D, Wilgenhof S, et al. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Mol Ther. 2012 May;20(5):1063–1074.
   PubMed Web of Science ®Google Scholar
• Eisenacher K, Steinberg C, Reindl W, et al. The role of viral nucleic acid recognition in dendritic cells for innate and adaptive antiviral immunity. Immunobiology. 2007;212(9–10):701–714.
   PubMed Web of Science ®Google Scholar
• Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019;4:7.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Mc Cafferty S, Combes F, et al. mRNA therapeutics deliver a hopeful message. Nano Today. 2018 Dec 01;23:16–39.
   Web of Science ®Google Scholar
• Kariko K, Buckstein M, Ni H, et al. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005 Aug;23(2):165–175.
   PubMed Web of Science ®Google Scholar
• Anderson BR, Muramatsu H, Jha BK, et al. Nucleoside modifications in RNA limit activation of 2ʹ-5ʹ-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucleic Acids Res. 2011 Nov;39(21):9329–9338.
   PubMed Web of Science ®Google Scholar
• Chen YH, Coller J, Universal A. Code for mRNA Stability? Trends Genet. 2016 Nov;32(11):687–688.
   PubMed Web of Science ®Google Scholar
• Orlandini von Niessen AG, Poleganov MA, Rechner C, et al. Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3ʹ UTRs Identified by Cellular Library Screening. Mol Ther. 2019 Apr 10;27(4):824–836.
   PubMed Web of Science ®Google Scholar
• Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun. 2018 Jul 6;9(1):2629.
   PubMed Web of Science ®Google Scholar
• Li J, Wang W, He Y, et al. Structurally programmed assembly of translation initiation nanoplex for superior mRNA delivery. ACS Nano. 2017 Mar 28;11(3):2531–2544.
   PubMed Web of Science ®Google Scholar
• Fotin-Mleczek M, Hoerr I Rna encoding a tumor antigen. Google Patents; 2019.
   Google Scholar
• Johanning F, Conry R, LoBuglio A, et al. A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo. Nucleic Acids Res. 1995;23(9):1495–1501.
   PubMed Web of Science ®Google Scholar
• Benteyn D, Heirman C, Bonehill A, et al. mRNA-based dendritic cell vaccines. Expert Rev Vaccines. 2015 Feb;14(2):161–176.
   PubMed Web of Science ®Google Scholar
• Qiu P, Ziegelhoffer P, Sun J, et al. Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization. Gene Ther. 1996 3;Mar(3):262–268.
   Google Scholar
• Steitz J, Britten CM, Wolfel T, et al. Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunol Immunother. 2006 Mar;55(3):246–253.
   PubMed Web of Science ®Google Scholar
• Johansson DX, Ljungberg K, Kakoulidou M, et al. Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One. 2012;7(1):e29732.
   PubMed Web of Science ®Google Scholar
• Broderick KE, Humeau LM. Electroporation-enhanced delivery of nucleic acid vaccines. Expert Rev Vaccines. 2015 Feb;14(2):195–204.
   PubMed Web of Science ®Google Scholar
• Hoerr I, Obst R, Rammensee HG, et al. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 2000 Jan;30(1):1–7.
   PubMed Web of Science ®Google Scholar
• Schlake T, Thess A, Fotin-Mleczek M, et al. Developing mRNA-vaccine technologies. RNA Biol. 2012 Nov;9(11):1319–1330.
   PubMed Web of Science ®Google Scholar
• Kallen KJ, Heidenreich R, Schnee M, et al. A novel, disruptive vaccination technology: self-adjuvanted RNActive((R)) vaccines. Hum Vaccin Immunother. 2013 Oct;9(10):2263–2276.
   PubMed Web of Science ®Google Scholar
• Heidenreich R, Jasny E, Kowalczyk A, et al. A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. Int J Cancer. 2015 Jul 15;137(2):372–384.
   PubMed Web of Science ®Google Scholar
• Kariko K, Muramatsu H, Ludwig J, et al. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011 Nov;39(21):e142.
   PubMed Web of Science ®Google Scholar
• Kanasty R, Dorkin JR, Vegas A, et al. Delivery materials for siRNA therapeutics. Nat Mater. 2013 Nov;12(11):967–977.
   PubMed Web of Science ®Google Scholar
• Geall AJ, Verma A, Otten GR, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14604–14609.
   PubMed Web of Science ®Google Scholar
• Pardi N, Tuyishime S, Muramatsu H, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015 Nov;10(217):345–351.
   Web of Science ®Google Scholar
• Akinc A, Querbes W, De S, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010 Jul;18(7):1357–1364.
   PubMed Web of Science ®Google Scholar
• Bahl K, Senn JJ, Yuzhakov O, et al. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Mol Ther. 2017 Jun 7;25(6):1316–1327.
   PubMed Web of Science ®Google Scholar
• Ratajczak MZ, Ratajczak J. Horizontal transfer of RNA and proteins between cells by extracellular microvesicles: 14 years later. Clin Transl Med. 2016 Mar;5(1):7.
   PubMedGoogle Scholar
• Tan L, Sun X. Recent advances in mRNA vaccine delivery. Nano Res. 2018;11(10):5338–5354.
   Web of Science ®Google Scholar
• Conry RM, LoBuglio AF, Wright M, et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 1995 Apr 1;55(7):1397–1400.
   PubMed Web of Science ®Google Scholar
• Granstein RD, Ding W, Ozawa H. Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA. J Invest Dermatol. 2000 Apr;114(4):632–636.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Selmi A, Diken M, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res. 2010 Nov 15;70(22):9031–9040.
   PubMed Web of Science ®Google Scholar
• Bialkowski L, van Weijnen A, Van der Jeught K, et al. Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours. Sci Rep. 2016 Mar 2;6:22509.
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017 Jul 13;547(7662):222–226.
   PubMed Web of Science ®Google Scholar
• Zhou WZ, Hoon DS, Huang SK, et al. RNA melanoma vaccine: induction of antitumor immunity by human glycoprotein 100 mRNA immunization. Hum Gene Ther. 1999 Nov 1;10(16):2719–2724.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Diken M, Selmi A, et al. FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines. Methods Mol Biol. 2016;1428:163–175.
   PubMedGoogle Scholar
• Kreiter S, Diken M, Selmi A, et al. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res. 2011 Oct 1;71(19):6132–6142.
   PubMed Web of Science ®Google Scholar
• Van Lint S, Goyvaerts C, Maenhout S, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res. 2012 Apr 1;72(7):1661–1671.
   PubMed Web of Science ®Google Scholar
• Uchida S, Yoshinaga N, Yanagihara K, et al. Designing immunostimulatory double stranded messenger RNA with maintained translational activity through hybridization with poly A sequences for effective vaccination. Biomaterials. 2018 Jan;150:162–170.
   PubMed Web of Science ®Google Scholar
• Scheel B, Aulwurm S, Probst J, et al. Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol. 2006 Oct;36(10):2807–2816.
   PubMed Web of Science ®Google Scholar
• Van der Jeught K, Joe PT, Bialkowski L, et al. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-beta and the ectodomain of the TGF-beta receptor II potentiates antitumor immunity. Oncotarget. 2014 Oct 30;5(20):10100–10113.
   PubMedGoogle Scholar
• Van Lint S, Renmans D, Broos K, et al. Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunol Res. 2016 Feb;4(2):146–156.
   PubMed Web of Science ®Google Scholar
• Rittig SM, Haentschel M, Weimer KJ, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther. 2011 May;19(5):990–999.
   PubMed Web of Science ®Google Scholar
• Rittig SM, Haentschel M, Weimer KJ, et al. Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. Oncoimmunology. 2016 5;May(5):e1108511.
   Web of Science ®Google Scholar
• Fotin-Mleczek M, Duchardt KM, Lorenz C, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother. 2011 Jan;34(1):1–15.
   PubMed Web of Science ®Google Scholar
• Weide B, Pascolo S, Scheel B, et al. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother. 2009 Jun;32(5):498–507.
   PubMed Web of Science ®Google Scholar
• Kowalczyk A, Doener F, Zanzinger K, et al. Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity. Vaccine. 2016 Jul 19;34(33):3882–3893.
   PubMed Web of Science ®Google Scholar
• Sebastian M, Schroder A, Scheel B, et al. A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer. Cancer Immunol Immunother. 2019 May;68(5):799–812.
   PubMed Web of Science ®Google Scholar
• Papachristofilou A, Hipp MM, Klinkhardt U, et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer. 2019 Feb 8;7(1):38.
   PubMed Web of Science ®Google Scholar
• Kubler H, Scheel B, Gnad-Vogt U, et al. Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer. 2015;3:26.
   PubMed Web of Science ®Google Scholar
• Rausch S, Schwentner C, Stenzl A, et al. mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Hum Vaccin Immunother. 2014;10(11):3146–3152.
   PubMed Web of Science ®Google Scholar
• Fotin-Mleczek M, Zanzinger K, Heidenreich R, et al. mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol. 2014 Aug 15;9:180.
   PubMed Web of Science ®Google Scholar
• Hess PR, Boczkowski D, Nair SK, et al. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol Immunother. 2006 Jun;55(6):672–683.
   PubMed Web of Science ®Google Scholar
• Kranz LM, Diken M, Haas H, et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016 Jun 16;534(7607):396–401.
   PubMed Web of Science ®Google Scholar
• Hongxia Z, Xinru Y, Xiaojuan W, et al. Abstract LB-205: A lipoplex-based mRNA nanovaccine for cancer immunotherapy. Cancer Res. 2019;79(13 Suppl):Abstract nr LB-205.
   Google Scholar
• Baldin AV, Savvateeva LV, Bazhin AV, et al. Dendritic cells in anticancer vaccination: rationale for Ex vivo loading or in vivo targeting. Cancers (Basel). 2020;12(3):590.
   Web of Science ®Google Scholar
• Guevara ML, Jilesen Z, Stojdl D, et al. Codelivery of mRNA with alpha-galactosylceramide using a new lipopolyplex formulation induces a strong antitumor response upon intravenous administration. ACS Omega. 2019 Aug 20;4(8):13015–13026.
   PubMed Web of Science ®Google Scholar
• Jabulowsky RA, Loquai C, Mitzel-Rink H, et al. Abstract CT156: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma. Cancer Res. 2018;78(13 Suppl):Abstract nr CT156.
   Google Scholar
• Wang C, Dickie J, Sutavani RV, et al. Targeting head and neck cancer by vaccination. Front Immunol. 2018;9:830.
   PubMed Web of Science ®Google Scholar
• Chen R, Zhang H, Yan J, et al. Scaffold-mediated delivery for non-viral mRNA vaccines. Gene Ther. 2018 Dec;25(8):556–567.
   PubMed Web of Science ®Google Scholar
• Blakney AK, McKay PF, Yus BI, et al. Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. Gene Ther. 2019 Sep;26(9):363–372.
   PubMed Web of Science ®Google Scholar
• Phua KK, Staats HF, Leong KW, et al. Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Sci Rep. 2014 Jun;4(4):5128.
   PubMed Web of Science ®Google Scholar
• Fan YN, Li M, Luo YL, et al. Cationic lipid-assisted nanoparticles for delivery of mRNA cancer vaccine. Biomater Sci. 2018 Nov 1;6(11):3009–3018.
   PubMed Web of Science ®Google Scholar
• Oberli MA, Reichmuth AM, Dorkin JR, et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 2017 Mar 8;17(3):1326–1335.
   PubMed Web of Science ®Google Scholar
• Miao L, Li L, Huang Y, et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019 Oct;37(10):1174–1185.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang L, Xu Z, et al. mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma. Mol Ther. 2018 Feb 7;26(2):420–434.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang Y, Miao L, et al. Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer. Mol Ther. 2018 Jan 3;26(1):45–55.
   PubMed Web of Science ®Google Scholar
• Haabeth OAW, Blake TR, McKinlay CJ, et al. mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):E9153–e9161.
   PubMed Web of Science ®Google Scholar
• McKinlay CJ, Vargas JR, Blake TR, et al. Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals. Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E448–e456.
   PubMed Web of Science ®Google Scholar
• Persano S, Guevara ML, Li Z, et al. Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials. 2017 May;125:81–89.
   PubMed Web of Science ®Google Scholar
• Le Moignic A, Malard V, Benvegnu T, et al. Preclinical evaluation of mRNA trimannosylated lipopolyplexes as therapeutic cancer vaccines targeting dendritic cells. J Control Release. 2018 May;28(278):110–121.
   Web of Science ®Google Scholar
• Boczkowski D, Nair SK, Snyder D, et al. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med. 1996 Aug 1;184(2):465–472.
   PubMed Web of Science ®Google Scholar
• Dannull J, Nair S, Su Z, et al. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood. 2005 Apr 15;105(8):3206–3213.
   PubMed Web of Science ®Google Scholar
• Aerts-Toegaert C, Heirman C, Tuyaerts S, et al. CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur J Immunol. 2007 Mar;37(3):686–695.
   PubMed Web of Science ®Google Scholar
• Grunebach F, Kayser K, Weck MM, et al. Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes. Cancer Gene Ther. 2005 Sep;12(9):749–756.
   PubMed Web of Science ®Google Scholar
• Bontkes HJ, Kramer D, Ruizendaal JJ, et al. Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells. Clin Immunol. 2008 Jun;127(3):375–384.
   PubMed Web of Science ®Google Scholar
• Bontkes HJ, Kramer D, Ruizendaal JJ, et al. Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther. 2007 Feb;14(4):366–375.
   PubMed Web of Science ®Google Scholar
• Dorrie J, Schaft N, Muller I, et al. Introduction of functional chimeric E/L-selectin by RNA electroporation to target dendritic cells from blood to lymph nodes. Cancer Immunol Immunother. 2008 Apr;57(4):467–477.
   PubMed Web of Science ®Google Scholar
• Bonehill A, Tuyaerts S, Van Nuffel AM, et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther. 2008 Jun;16(6):1170–1180.
   PubMed Web of Science ®Google Scholar
• Van Lint S, Wilgenhof S, Heirman C, et al. Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. Cancer Immunol Immunother. 2014 Sep;63(9):959–967.
   PubMed Web of Science ®Google Scholar
• Pen JJ, De Keersmaecker B, Maenhout SK, et al. Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70. J Immunol. 2013 Aug 15;191(4):1976–1983.
   PubMed Web of Science ®Google Scholar
• Wilgenhof S, Van Nuffel AM, Corthals J, et al. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother. 2011 Jun;34(5):448–456.
   PubMed Web of Science ®Google Scholar
• Wilgenhof S, Van Nuffel AM, Benteyn D, et al. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol. 2013 Oct;24(10):2686–2693.
   PubMed Web of Science ®Google Scholar
• Bol KF, Figdor CG, Aarntzen EH, et al. Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. Oncoimmunology. 2015 Aug;4(8):e1019197.
   PubMed Web of Science ®Google Scholar
• Kyte JA, Aamdal S, Dueland S, et al. Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. Oncoimmunology. 2016;5(11):e1232237.
   PubMed Web of Science ®Google Scholar
• Kyte JA, Mu L, Aamdal S, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 2006 Oct;13(10):905–918.
   PubMed Web of Science ®Google Scholar
• DeBenedette MA, Calderhead DM, Tcherepanova IY, et al. Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8+/CD28+ cytotoxic T-cell responses in vitro. J Immunother. 2011;34(1):45–57.
   PubMed Web of Science ®Google Scholar
• Amin A, Dudek AZ, Logan TF, et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): phase 2 study results. J Immunother Cancer. 2015;3:14.
   PubMed Web of Science ®Google Scholar
• Figlin RA, Tannir NM, Uzzo RG, et al. Results of the ADAPT trial; a randomized Phase III study of Rocapuldencel-T an autologous dendritic cell–based vaccine, in combination with sunitinib as first-line therapy in patients with groups metastatic clear-cell renal cell carcinoma. Clin Cancer Res. 2020;26(10):2327–2336.
   PubMed Web of Science ®Google Scholar
• Wilgenhof S, Corthals J, Heirman C, et al. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol. 2016 Apr 20;34(12):1330–1338.
   PubMed Web of Science ®Google Scholar
• Tureci O, Vormehr M, Diken M, et al. Targeting the heterogeneity of cancer with individualized neoepitope vaccines. Clin Cancer Res. 2016 Apr 15;22(8):1885–1896.
   PubMed Web of Science ®Google Scholar
• Kreiter S, Vormehr M, van de Roemer N, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015 Apr 30;520(7549):692–696.
   PubMed Web of Science ®Google Scholar
• Van Hoecke L, Saelens X. Therapeutic anti-tumor immunity directed against neo-epitopes by intratumor delivery of mRNA encoding MLKL. Cell Stress. 2018 Oct 2;2(10):279–281.
   PubMed Web of Science ®Google Scholar
• Van Hoecke L, Van Lint S, Roose K, et al. Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes. Nat Commun. 2018 Aug 24;9(1):3417.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 Jul 13;547(7662):217–221.
   PubMed Web of Science ®Google Scholar
• Hoang-Le D, Smeenk L, Anraku I, et al. A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy. Gene Ther. 2009 Feb;16(2):190–199.
   PubMed Web of Science ®Google Scholar
• Garcia-Hernandez Mde L, Gray A, Hubby B, et al. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res. 2008 Feb 1;68(3):861–869.
   PubMed Web of Science ®Google Scholar
• Pepini T, Pulichino AM, Carsillo T, et al. Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design. J Immunol. 2017 May 15;198(10):4012–4024.
   PubMed Web of Science ®Google Scholar
• Beissert T, Koste L, Perkovic M, et al. Improvement of in vivo expression of genes delivered by self-amplifying RNA using vaccinia virus immune evasion proteins. Hum Gene Ther. 2017 Dec;28(12):1138–1146.
   PubMed Web of Science ®Google Scholar
• Slovin SF, Kehoe M, Durso R, et al. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine. 2013 Jan 30;31(6):943–949.
   PubMed Web of Science ®Google Scholar
• Morse MA, Hobeika A, Gwin W, et al. Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients. J Immunother Cancer. 2015;3(2):P444.
   Google Scholar
• Fotin-Mleczek M, Zanzinger K, Heidenreich R, et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J Gene Med. 2012 Jun;14(6):428–439.
   PubMed Web of Science ®Google Scholar
• Grabbe S, Haas H, Diken M, et al. Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma. Nanomedicine (Lond). 2016 Oct;11(20):2723–2734.
   PubMed Web of Science ®Google Scholar
• Faghfuri E, Faramarzi MA, Nikfar S, et al. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert Rev Anticancer Ther. 2015;15(9):981–993.
   PubMed Web of Science ®Google Scholar